Coronary atherosclerotic heart disease
Conditions
Interventions
Experimental Group:Patients in the experimental group received intravenous tirofiban immediately after PCI
Control Group:Patients in the control group received intravenous 0.9% sodium chloride solution (normal saline) immediately after PCI
Sponsors
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.adult patients over 18 years old; 2.Percutaneous coronary angiography showed that the degree of vascular stenosis was more than 75%, and the target vessel met the criteria for interventional therapy; And the target lesions to be treated were complex lesions (multi-vessel disease, target lesion required stent length > 30mm or total stent length > 60mm, left main coronary artery (>=50%) or proximal LAD (>=70%), calcified target lesion requiring atherectomy, bifurcation lesion requiring stent number >=2 and chronic occlusive disease); 3.patients with clinical comorbidities (diabetes or chronic kidney disease with glomerular filtration rate < 60ml/min); 4.patients who had not used antiplatelet aggregation drugs before surgery and received dual antiplatelet drugs at conforming dose (aspirin 300mg+ ticagrelor 180mg) for the first time before surgery or received conventional dose of dual antiplatelet drugs (aspirin 100mg once daily + ticagrelor 90mg twice daily) during the observation period; The cumulative dose reached the loading dose.
Exclusion criteria
Exclusion criteria: 1.age < 18 years old; 2.antiplatelet drugs were contraindicated; 3.emergency PCI or STEMI patients; 4.previous history of revascularization for stroke or myocardial infarction; 5.planned surgery within 30 days; 6.need for long-term oral anticoagulants; 7.extreme risk for active or major bleeding (e.g., active peptic ulcer disease, gastrointestinal pathology with higher bleeding risk, malignancy with higher bleeding risk); 8.extreme risk for active or major bleeding (e.g., active peptic ulcer disease, gastrointestinal pathology with higher bleeding risk, malignancy with higher bleeding risk); 9.the expected survival time was less than 1 year; 10.women who are pregnant or lactating; 11.platelet count < 100*10^9/L; 12.unable or unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ischemic Events;Bleeding Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of composite endpoint at 7 days postoperatively; | — |
Countries
China
Contacts
Public ContactChunxia Zhao
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Outcome results
None listed